CT shows Large recurrent second scan tumor at the ileocolic anastomosis with transmural invasion into the duodenum,...

Colorectal CancerNovember 14, 2025Navis AI

Ask Navis about your situation

This answer is general. Get one about your specific case — no signup, answered right here.

or Upload your records for answers about your actual case

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Question asked:

CT shows Large recurrent second scan tumor at the ileocolic anastomosis with transmural invasion into the duodenum, abutment of the pancreatic head, spread to right abdominal wall muscle, peritoneal carcinomatosis, and regional nodes. No liver mets or ascites. There’s also a para-umbilical hernia with bowel inside, not incarcerated. This is stage IV with peritoneal disease and a locally invasive bowel mass at a prior anastomosisRight paracolic mass, infiltrative, with contiguous involvement of small bowel and contact with D2 duodenum; loss of fat planes posteriorly toward the right kidney. Locoregional nodes present. New right-upper-lobe lung nodule with spiculated margins → metastatic deposit. No focal liver lesion is described in this report. If another scan says otherwise, treat that as progression as well; the systemic plan below is unchanged. Right para-umbilical hernia with omentum and bowel; not incarcerated. Prostatomegaly. Background bibasal interstitial/fibrotic lung changes. second scan CT shows Large recurrent second scan tumor at the ileocolic anastomosis with transmural invasion into the duodenum, abutment of the pancreatic head, spread to right abdominal wall muscle, peritoneal carcinomatosis, and regional nodes. No liver mets or ascites. There’s also a para-umbilical hernia with bowel inside, not incarcerated. This is stage IV with peritoneal disease and a locally invasive bowel mass at a prior anastomosisRight paracolic mass, infiltrative, with contiguous involvement of small bowel and contact with D2 duodenum; loss of fat planes posteriorly toward the right kidney. Locoregional nodes present. New right-upper-lobe lung nodule with spiculated margins → metastatic deposit. No focal liver lesion is described in this report. If another scan says otherwise, treat that as progression as well; the systemic plan below is unchanged. Right para-umbilical hernia with omentum and bowel; not incarcerated. Prostatomegaly. Background bibasal interstitial/fibrotic lung changes. What the ctDNA shows KRAS G12D (pathogenic), TP53 R248Q (pathogenic), APC truncation. BRAF V600E not detected, NRAS/PIK3CA/SMAD4 negative, HER2 amplification not detected, NTRK fusion not detected. Microsatellite stable and TMB-low. Implications: primary resistance to anti-EGFR therapy; immunotherapy is unlikely to help in MSS/TMB-low mCRC; no clear level-1/2 targetable alteration. patient bleeding hb 9 on clipodogrel for stent

Clinical Summary & Treatment Implications for Recurrent Stage IV CRC

This is a complex, heavily pretreated case with significant molecular and anatomic constraints. Let me parse the key oncologic and practical considerations:

Molecular Profile & Therapeutic Implications

Genotype Summary:

KRAS G12D (pathogenic): Confers primary resistance to anti-EGFR monoclonal antibodies (cetuximab, panitumumab)
TP53 R248Q (pathogenic): Associated with aggressive biology and reduced chemotherapy responsiveness
APC truncation: Early driver mutation; consistent with CRC pathogenesis
MSS/TMB-low: Excludes checkpoint inhibitor monotherapy as per ASCO/NCCN guidelines for mCRC

Per NCCN Guidelines for Metastatic CRC (2024):

KRAS-mutant, MSS tumors have limited targeted options; standard-of-care remains cytotoxic chemotherapy ± bevacizumab or anti-VEGF agents
Anti-PD-1/PD-L1 monotherapy is not recommended for MSS/TMB-low disease (Level 1 evidence from KEYNOTE-177, CheckMate-142)
EGFR-directed therapy is contraindicated

Disease Burden & Staging

Metastatic Sites:

Peritoneal carcinomatosis (M1c per AJCC v8)
Pulmonary metastasis (RUL nodule, spiculated margins)
Locoregional nodal involvement
Locally advanced primary: Transmural invasion into duodenum, pancreatic head abutment, right abdominal wall infiltration

Prognostic Considerations:

Peritoneal involvement + pulmonary disease = high-risk metastatic pattern
Recurrent disease at anastomosis suggests aggressive biology
TP53 mutation associated with worse prognosis in mCRC

Critical Clinical Issues

1. Anemia (Hb 9 g/dL) + Clopidogrel Exposure

Immediate concern: Dual bleeding risk

Clopidogrel increases hemorrhage risk, particularly with transmural invasion into duodenum
Hb 9 is borderline for chemotherapy tolerance
Recommendation:
- Cardiology/interventional consultation regarding stent type and P2Y12 inhibitor necessity
- If stent is bare-metal (BMS) and >1 month post-placement, consider deprioritizing clopidogrel during active chemotherapy
- If drug-eluting stent (DES) recently placed, discuss risk-benefit with cardiologist
- Transfusion threshold: Consider maintaining Hb ≥10 g/dL during chemotherapy

2. Locally Invasive Primary + Peritoneal Disease

Surgical considerations (per NCCN):

Transmural duodenal invasion + pancreatic head abutment = likely unresectable primary
Peritoneal carcinomatosis typically contraindicates cytoreductive surgery (CRS) unless oligometastatic pattern
Exception: If excellent response to neoadjuvant chemotherapy, reassess resectability
Para-umbilical hernia: Non-incarcerated; defer repair until disease response assessed

Recommended Treatment Approach

First-Line Systemic Therapy Options:

Option A: FOLFOXIRI + Bevacizumab (NCCN Category 1)

Rationale:
- Superior OS vs. FOLFIRI + bevacizumab in TRIBE trial (HR 0.74, p=0.041) for fit patients
- Addresses high disease burden (peritoneal + pulmonary)
- No reliance on EGFR or immunotherapy
Caveat: Increased toxicity; requires careful monitoring with Hb 9 baseline
Dosing consideration: May require dose reduction (e.g., 80% FOLFOXIRI) given anemia

Option B: FOLFIRI + Bevacizumab (NCCN Category 1)

Rationale:
- Less toxic than FOLFOXIRI
- Still appropriate for KRAS-mutant disease
- Better tolerated with baseline anemia
Evidence: FIRE-3 trial showed bevacizumab + FOLFIRI is standard for KRAS-mutant mCRC

Option C: FOLFOX + Bevacizumab (Alternative)

Consider if irinotecan contraindicated (e.g., UGT1A1 polymorphism, prior toxicity)

Bevacizumab Rationale:

KRAS-mutant tumors retain VEGF-dependency
Bevacizumab + chemotherapy improves OS in mCRC (NCCN Level 1)
Addresses peritoneal disease burden

Avoid:

❌ Anti-EGFR monoclonal antibodies (KRAS G12D resistance)
❌ Checkpoint inhibitors as monotherapy (MSS/TMB-low)
❌ BRAF inhibitors (BRAF V600E not detected)
❌ HER2-directed therapy (no amplification)

Biomarker-Driven Considerations

Potential future options if chemotherapy resistance develops:

KRAS G12D-specific inhibitors (sotorasib, adagrasib)
- FDA-approved for KRAS G12C; G12D efficacy data limited
- Consider if progression on chemotherapy + bevacizumab
- ASCO/NCCN: Emerging option, not yet standard first-line
TAS-102 (trifluridine/tipiracil)
- Approved for chemotherapy-refractory mCRC
- Reserve for later lines
Regorafenib
- Multikinase inhibitor; approved for refractory mCRC
- Consider if progression after 1-2 lines

Practical Management Plan

| Domain | Action | |---|---| | Cardiology | Clarify stent type; assess clopidogrel necessity; discuss bleeding risk | | Hematology | Transfuse to Hb ≥10 g/dL; monitor CBC weekly during chemo | | Baseline Labs | UGT1A1 genotyping (irinotecan dosing); LFTs, renal function | | Imaging | Baseline chest/abdomen/pelvis; reassess after 2-3 cycles | | Surgery | Defer hernia repair; reassess primary resectability after response | | Chemotherapy | Start FOLFIRI or FOLFOXIRI + bevacizumab (dose-reduced if needed) | | Supportive Care | Antiemetics, G-CSF prophylaxis; GI prophylaxis (PPI given duodenal involvement) |

Prognosis & Outcomes

Median OS for KRAS-mutant mCRC with peritoneal disease: 12–18 months with modern chemotherapy + bevacizumab (NCCN data)

Factors favoring response:

Good performance status (assumed)
No liver metastases (better prognosis than hepatic involvement)

Factors limiting prognosis:

TP53 co-mutation
Peritoneal carcinomatosis
Pulmonary metastases
Locally advanced primary

Sources

NCCN Clinical Practice Guidelines in Oncology: Colon Cancer (v3.2024) – Systemic therapy for mCRC, KRAS-mutant disease management
ASCO Guidelines: Metastatic Colorectal Cancer (2021 Update) – Immunotherapy exclusion criteria (MSS/TMB-low), bevacizumab recommendations
FDA Approvals: Sotorasib (KRAS G12C), bevacizumab (mCRC indication)

Critical next step: Multidisciplinary tumor board review (medical oncology, surgery,

Ask Navis about your case

That answer is general. Ask about your specific situation — no signup, answered right here.

or Upload your records for answers about your actual case

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →